Colgate's $1B+ Personal-Care Carve-Out Is the First Real Test of Whether a US Mega-Staples Can Cut Itself in Half

On September 11, 2026, Reuters reported that Colgate-Palmolive is working with Goldman Sachs to find buyers for three of its US mass-market personal-care brands: Softsoap (hand and body soap), Irish Spring (bar soap and body wash), and Speed Stick (deodorant and antiperspirant). Sources told Reuters the three brands could together fetch \"over $1 billion,\" though Colgate declined to comment. The company is exploring a piecemeal sale — only a few brands inside the personal-care unit — rather than a full segment divestiture.

For a 220-year-old US mega-staples that has bought brands more often than it has sold them — most recently adding EltaMD and PCA Skin in 2017 — the willingness to divest mass-market icons is itself the news. The deal is exploratory and no buyer has been named; Reuters sources said the brands will be sold in parts, not as a single block.

The personal-care business inside Colgate's Oral, Personal and Home Care segment is the most obvious candidate for divestiture precisely because it is the only piece of the US portfolio shrinking on every metric management reports. North America net sales fell to $891M in Q2 2026 from a year earlier (a 13.2% reported decline), with organic sales down 3.0% on volume down 3.0% and pricing down 3.9% — the third straight quarter of negative organic growth in the region.

Annual segment data from Colgate's 2025 10-K tells the longer story: North America personal-care net sales of $4,045M generated only $784M of operating profit (a 19.4% margin, down 100 basis points), with management attributing the decline to \"skin health, body wash and underarm protection.\" Those are exactly the categories Softsoap, Irish Spring, and Speed Stick occupy. Selling them is, in effect, Colgate-Palmolive acknowledging that the volume-and-pricing playbook of the 2010s no longer works in US mass deodorant and bar soap.

If three of the unit's biggest US brands can fetch only $1B, the implied multiple is well below what the consumer-staples M&A market has been paying for growth brands. Recent comparables cluster around 2x–4x sales for premium personal-care assets: Church & Dwight paid $880M for Touchland in May 2025, $325M for Miss Mouth's Messy Eater in May 2026, and $580M for TheraBreath in 2021. Henkel closed the OLAPLEX acquisition in July 2026 at roughly $2.06/share, valuing the premium hair-care brand at close to $2.4B on roughly $200M of revenue — north of 10x sales.

Reading the spread: Colgate-Palmolive is being asked to accept roughly 0.5–0.7x sales for mature, declining US bar soap and deodorant brands, while growth assets in the same category clear at 3–10x. The gap is not a negotiating mistake by Goldman — it is the market telling Colgate that mass deodorant and bar soap are structurally low-growth categories where private label and Dove/Secret are taking share. The implied message for Edgewell, which sold its feminine-care business to Essity for just $340M (about 1.1x sales) in February 2026, is that mature personal-care carve-outs clear at distressed multiples unless they carry growth optionality.

Church & Dwight is the most natural buyer in the universe. It is a serial, sub-$1B personal-care acquirer — Touchland, Miss Mouth's, TheraBreath, Hero, and Waterpik in the last 24 months — with a Consumer Domestic personal-care product line that generated $2,217.9M of external revenue in 2025 inside a $4,774.8M Consumer Domestic segment. Net debt/EBITDA is 1.78x and the company produced $1.165B of free cash flow over the trailing twelve months. A $1B bolt-on for Softsoap and Speed Stick would fit its balance sheet without leverage stress and round out a deodorant portfolio that today relies on Batiste (dry shampoo) and Trojan adjacencies.

The pecking order matters for the price. With Church & Dwight as the only strategic with both balance sheet and pattern recognition, the auction risk is that Henkel shows up, finds the soap overlap uncomfortable, and lets the price drift to PE — meaning Colgate likely clears closer to the $1B floor than the $1.5B peer-implied ceiling.

Colgate-Palmolive trades at 34.5x trailing earnings, 3.65x EV/Sales and 20.0x EV/EBITDA, with a market cap near $70.3B and net debt/EBITDA of 1.69x. Even at the low end of the rumored price — say $1.0B cash in — the company has three credible uses: (1) accelerate buybacks against $1.65B of TTM free cash flow; (2) pay down the $7.4B long-term debt stack visible on the balance sheet; or (3) fund premium personal-care acquisitions in skin health and oral care, the categories management is leaning into (EltaMD, PCA Skin, hello, Tom's of Maine).

Strategic-rationale aside, the deal also reframes the 2026 guidance picture. Management reaffirmed net-sales growth of 2–6% and organic growth of 1–4% for the year, with the 0.4% pet-food-exit drag baked in. A successful Softsoap/Speed Stick sale would let Colgate re-base 2027 organic growth guidance higher — removing roughly half of the unit's declining base — and that is precisely the play Unilever made after separating The Magnum Ice Cream Company in December 2025, where the company guided to 100bps of margin expansion post-demerger.

Colgate is not breaking new ground globally — it is joining a clear peer playbook. Haleon demerged from GSK in July 2022 at a £31B market cap, becoming the largest European listing of that decade and trading up materially as a focused consumer-healthcare story. Unilever finalized the spin-off of The Magnum Ice Cream Company in December 2025, with management explicitly guiding to 100bps of operating-margin uplift from the separation. Edgewell carved out its North America feminine-care business to Essity for $340M in February 2026.

What makes Colgate's move distinctive is that it is the first major US-domiciled staples incumbent — not a London-listed conglomerate — to voluntarily shrink its personal-care footprint for capital-allocation reasons. Procter & Gamble has been pruning the long tail (Charlie Banana in 2025) and trimming 7,000 jobs by mid-2027, but has not signaled a mass-deodorant carve-out. Colgate's move, if it closes, will raise the implicit question for every other US mega-staples board: \"Should we be doing this too?\" — and force a re-rating discussion that has so far been confined to European peers.

Short-term (days to quarters): The single most actionable signal will be Goldman Sachs' first round of bid letters, expected within 6–9 months if the process follows the standard staples playbook. Until then, watch Q3 2026 results (late October 2026) for any updated read on North America personal-care volume — a fourth straight negative organic print would harden the case for accelerated divestiture and could compress Colgate-Palmolive's 34.5x P/E toward 28–30x.

Long-term (1–3 years): Three milestones define the structural thesis. First, the close itself — proving a US mega-staples can execute a clean carve-out without brand-loyalty or retail-shelf disruption. Second, the redeployment — whether Colgate-Palmolive plows the cash into EltaMD-style premium M&A (skin health, therapeutics) or into buybacks that lift EPS without fixing the underlying growth problem. Third, the contagion — whether Procter & Gamble follows with its own mass-deodorant review or treats Colgate's exit as evidence to lean in, not out. The asymmetry favors the bull case for Church & Dwight: even at a $1B price, the deal would consolidate US mass soap and deodorant share behind a buyer that already has ARM & HAMMER and Trojan in the same aisle.